Robert F. Kennedy Jr vs GLP1
RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?
With the election of Donald Trump in 2024, a new cabinet of officials is due to be appointed to the White House and surrounding government agencies.
With those appointees is a decidedly anti GLP1 entrant – Robert Francis Kennedy Jr. ("RFK Jr"), who was appointed to the role of Secretary of Health and Human Services.
While it's not a foregone conclusion that RFK Jr. will seek to limit the availability of GLP1s or crack down on them, past statements make many a bit unsure of whether he will negatively affect availability of GLP1s.
Why do some think RFK Jr. is against GLP1s?
As reported by Newsweek, there are many instances in which RFK has railed against the current health system, and more importantly GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) in particular:
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
